|
melanoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Although MAGEA1's expression levels have been evaluated as one of the cancer testis (CT) antigens for immunotherapy in melanoma and several other cancers, its functional role and signaling mechanisms are largely unknown.
|
28459460 |
2017 |
|
melanoma
|
0.400 |
Biomarker
|
disease |
CTD_human |
PLX4032 Mediated Melanoma Associated Antigen Potentiation in Patient Derived Primary Melanoma Cells.
|
26640592 |
2015 |
|
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
There has been an explosion in CTA-based research since CTAs were first identified in 1991 and MAGE-1 was shown to elicit an autologous cytotoxic T-lymphocyte (CTL) response in a patient with melanoma.
|
22710665 |
2012 |
|
melanoma
|
0.400 |
AlteredExpression
|
disease |
LHGDN |
Transient down-regulation of DNMT1 methyltransferase leads to activation and stable hypomethylation of MAGE-A1 in melanoma cells.
|
16497664 |
2006 |
|
melanoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Clinical grade DC from melanoma patients were generated from blood monocytes and infected with a recombinant ALVAC virus encoding either a marker gene (EGFP) or the MAGE-1-MAGE-3 minigenes.
|
15665821 |
2005 |
|
melanoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Although MAGE-1 expression has been considered as a target for immunomodulation therapy, our findings do not indicate consistent expression of this epitope in a majority of melanomas.
|
15223957 |
2004 |
|
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Subsequently, we chose four sets of primers for the melanoma-associated antigens MAGE1, tyrosinase, Melan A/MART-1 and gp100/Pmel17 and performed PCR analysis over a range of cycle numbers.
|
11604998 |
2001 |
|
melanoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Using several different preexisting tumor models that make use of B16F10 melanoma cells expressing a target tumor antigen (human melanoma-associated gene [MAGE]-1), we found that vaccination with bone marrow-derived DCs engineered to express MAGE-1 via adenoviral-mediated gene transfer led to a dramatic decrease in the number of metastases in a lung metastasis model, and led to prolonged survival and some long-term cures in a subcutaneous preexisting tumor model.
|
10811863 |
2000 |
|
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Peptide sequences from MAGE-1, 2, 3, 4a, and 6 aligned to MAGE-12:170-178 were not recognized by F001-TIL.
|
10754339 |
2000 |
|
melanoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Knowledge of these mechanisms led to the design of a non-natural, minimally modified analogue of MAGE-1.A1, [Aib2, NMe-Ser8]MAGE-1.A1, which was highly peptidase-resistant and bound to MHC and activated MAGE-1.A1-specific anti-melanoma CTLs.
|
10187808 |
1999 |
|
melanoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Expression of MAGE-10 in melanoma tumors was found to parallel that of MAGE-1.
|
10446460 |
1999 |
|
melanoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
MAGE 1 and 3 gene expression was also not detected in any of the cases of benign and dysplastic melanocytic naevi and in situ MMs.
|
10215777 |
1999 |
|
melanoma
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
Transcription of the MAGE-1 gene and the methylation status of its Ets binding promoter elements: a quantitative analysis in melanoma cell lines using a real-time polymerase chain reaction technique.
|
10465576 |
1999 |
|
melanoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
To identify new CT antigens, we constructed an expression cDNA library from a melanoma cell line that expresses a wide range of CT antigens and screened the library with an allogeneic melanoma patient serum known to contain antibodies against two CT antigens, MAGE-1 and NY-ESO-1. cDNA clones isolated from this library identified four CT antigen genes: MAGE-4a, NY-ESO-1, LAGE-1, and CT7.
|
9618514 |
1998 |
|
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Incubation of transduced HLA-A1 expressing melanoma cell lines with 2 anti-MAGE-1.A1 CTL clones resulted in specific recognition and lysis of target cells, indicating that the exogenous MAGE-1 protein was processed and presented in a normal manner.
|
9378539 |
1997 |
|
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
PCR-based analysis of the freshly harvested tumor from patient PM2-B2 revealed the presence of message for the melanoma-associated gene products MAGE-1 and MAGE-3, but not for tyrosinase or MART-1/MELAN-A.
|
9816095 |
1996 |
|
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
These results suggest a pattern of TCR conservation in CTL selected for recognition of MAGE-1 or BAGE peptides on the autoiogous melanoma.
|
8921424 |
1996 |
|
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Immunohistology is thus a rapid and well-established method that might be used to select and monitor HLA-A1 positive patients with malignant melanoma and other candidate tumours for MAGE-1-directed immuno-therapy.
|
8917707 |
1996 |
|
melanoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
It has previously been reported that MAGE-1, -2, -3 and -4 genes are expressed in human cancers including cutaneous melanoma.
|
8647642 |
1996 |
|
melanoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The MAGE-1 and MAGE-3 genes are expressed in tumors of different histotypes but not in normal adult tissues (with the exception of testis), while the MART-1 gene appears to be selectively expressed in melanoma.
|
8900375 |
1996 |
|
melanoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The human genes MAGE-1 and -3 encode melanoma peptide antigens that are recognized by autologous cytotoxic T lymphocytes.
|
7591261 |
1995 |
|
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The genes MAGE-1 and MAGE-3 both encode melanoma peptide antigens recognized by major histocompatibility complex-restricted cytotoxic T lymphocytes.
|
7557134 |
1995 |
|
melanoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
These results suggest that this type of autologous ex vivo cultured population of professional APC, when pulsed with the relevant-CTL-determined peptide, can serve as a novel type of candidate vaccine for active specific immunization against HLA-A1-positive patients with melanoma expressing the MAGE-1 antigen.
|
7750125 |
1995 |
|
melanoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Serological typing of normal and tumor cell lysates was in full agreement with mRNA analysis, showing expression of MAGE-1 protein in MAGE-1 mRNA-positive testis and a subset of melanomas but not in MAGE-1 mRNA-negative normal or tumor tissues.
|
8302824 |
1994 |
|
melanoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
5-Aza-2'-deoxycytidine (DAC), a demethylating agent, was capable of inducing MAGE-1 expression by a MAGE-1-negative melanoma cell line 888-mel as well as by a number of other melanoma cell lines.
|
7511051 |
1994 |